ニュージャージーにおける卵巣上皮性癌の臨床試験
ニュージャージー内の拠点で、卵巣上皮性癌に関する9件の研究が参加者を募集しています。
ニュージャージー内の都市
公式研究テキスト（英語）
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- John Theurer Cancer Center /ID# 275756, Hackensack
- Rutgers Cancer Institute of New Jersey /ID# 274358, New Brunswick
- Holy Name Medical Center /ID# 276240, Teaneck
被験者募集中第2相
18歳以上 · 女性 · 2026/09/29更新 · NCT06890338A Study of Isoquercetin in People With Ovarian Cancer
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/15更新 · NCT07303894ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Astera Cancer Care, East Brunswick
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/14更新 · NCT05059444AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
- Research Site, Camden
被験者募集中第3相
18歳以上 · 女性 · 2026/07/21更新 · NCT07218809Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Valley Health System, Paramus
被験者募集中第3相
18歳以上 · 女性 · 2026/07/02更新 · NCT06819007A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
被験者募集中
18歳以上 · 女性 · 2026/07/01更新 · NCT05429970CT-95 in Advanced Cancers Associated With Mesothelin Expression
- Context Investigational Site, Hackensack
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/12更新 · NCT06756035A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
- John Theurer Cancer Center Hackensack University Medical Center, Hackensack
被験者募集中第1相
18歳以上 · 女性 · 2026/02/03更新 · NCT06469281CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
- Rutgers Cancer Institute, New Brunswick
被験者募集中第2相
18歳以上 · 女性 · 2025/12/23更新 · NCT06690775ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。